Skip to content
BioVac
-
AfDB invests US$15M in Biovac to advance African vaccine manufacturing sovereignty
The financing forms part of Biovac’s expansion programme, which aims to increase the company’s annual manufacturing capacity to as many as 500 million vaccine doses.
-
Africa CDC backs US$180M Biovac deal to end vaccine import dependence
The financing consortium includes Proparco, the European Investment Bank through the Human Development Accelerator initiative, and the International Finance Corporation.
-
Biovac secures USD108M for Africa’s first integrated vaccine manufacturing hub
Biovac will construct the new facility at its Cape Town manufacturing site, with completion expected by 2028.